Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silo Pharma (SILO) Cash from Financing Activities (2019 - 2025)

Silo Pharma (SILO) has disclosed Cash from Financing Activities for 6 consecutive years, with $2.1 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities changed N/A to $2.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.5 million through Dec 2025, up 39.06% year-over-year, with the annual reading at $4.9 million for FY2025, 49.93% up from the prior year.
  • Cash from Financing Activities hit $2.1 million in Q4 2025 for Silo Pharma, up from $634922.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $3.8 million in Q1 2021 to a low of -$194423.0 in Q4 2023.
  • Historically, Cash from Financing Activities has averaged $1.1 million across 4 years, with a median of $634922.0 in 2025.
  • Biggest YoY gain for Cash from Financing Activities was 25209.79% in 2021; the steepest drop was 100.11% in 2021.
  • Year by year, Cash from Financing Activities stood at -$2366.0 in 2021, then crashed by 8117.37% to -$194423.0 in 2023, then skyrocketed by 995.74% to $1.7 million in 2024, then grew by 22.38% to $2.1 million in 2025.
  • Business Quant data shows Cash from Financing Activities for SILO at $2.1 million in Q4 2025, $634922.0 in Q3 2025, and $1.7 million in Q3 2024.